The high-risk pedigree (HRP) design is an established strategy to discover rare, highly-2 penetrant, Mendelian-like causal variants. Its success, however, in complex traits has been 3 modest, largely due to challenges of genetic heterogeneity and complex inheritance models. We 4 describe a HRP strategy that addresses intra-familial heterogeneity, and identifies inherited 5 segments important for mapping regulatory risk. We illustrate this new Shared Genomic 6 Segment (SGS) method in 11 extended, Utah, multiple myeloma (MM) HRPs, and subsequent 7 exome sequencing in SGS regions of interest in 1064 MM/MGUS (monoclonal gammopathy of 8 undetermined significance -a precursor to MM) cases and 964 controls from a jointly-called 9 collaborative resource, including cases from the initial 11 HRPs. One genome-wide significant 10 1.8 Mb shared segment was found at 6q16. Exome sequencing in this region revealed predicted 11 deleterious variants in USP45 (p.Gln691*, p.Gln621Glu), a gene known to influence DNA repair 12 through endonuclease regulation. Additionally, a 1.2 Mb segment at 1p36.11 is inherited in two 13 Utah HRPs, with coding variants identified in ARID1A (p.Ser90Gly, p.Met890Val), a key gene in 14 the SWI/SNF chromatin remodeling complex. Our results provide compelling statistical and 15 genetic evidence for segregating risk variants for MM. In addition, we demonstrate a novel 16 strategy to use large HRPs for risk-variant discovery more generally in complex traits.
INTRODUCTION
Rare risk variants have been suggested as a source of missing heritability in the majority 14 of complex traits [1] [2] [3] . High-risk pedigrees (HRPs) are a mainstay for identifying rare, highly 15 penetrant, Mendelian-like causal variants [4] [5] [6] [7] [8] [9] [10] [11] . However, while successful for relatively 16 simple traits, genetic heterogeneity remains a major obstacle that reduces the effectiveness of 17 HRPs for gene mapping in complex traits [12, 13] . Also challenging is mapping regulatory 18 variants, likely to be important for complex traits, necessitating interrogation outside the well- 19 annotated coding regions of the genome [14, 15] . Localizing chromosomal regions to target the 20 search for rare risk variants will be instrumental in mapping them. 21 Here we develop a HRP strategy based on our previous Shared Genomic Segment 22 (SGS) approach [16] that focuses on pedigrees sufficiently large to singularly identify 23 4 segregating chromosomal segments of statistical merit. The method addresses genetic 1 heterogeneity by optimizing over all possible subsets of studied cases in a HRP. Key to the 2 utility of the method is the derivation of significance thresholds for interpretation. These 3 thresholds address the genome-wide search and the multiple testing, inherent from the 4 optimization, through use of distribution fitting and the Theory of Large Deviations. 5 We apply this novel method to 11 MM HRPs, and use exome sequencing from a 6 collaborative resource of 68 multiplex MM pedigrees to perform subsequent targeted searches 7 at the variant level. MM is a complex cancer of the plasma cells with 30,330 new cases annually 8 (incidence 6.5/100,000 per year) [17] . Despite survival dramatically increasing from 25.8% in 9 1980 to 48.5% in 2012, MM remains a cancer with one of the lowest 5-year survival rates in 10 adult hematological malignancies [17] . MM is preceded by a condition referred to as monoclonal 11 gammopathy of undetermined significance (MGUS) . Evidence for the familial clustering of MM is 12 consistently replicated [18] [19] [20] [21] , as is its clustering with MGUS [22] [23] [24] [25] . Genetic pedigree studies 13 in MM are scarce as it remains a challenge to acquire samples in pedigrees due to rarity and 14 low survival rates. The Utah MM HRPs are one of only a few pedigree resources worldwide and 15 contains unparalleled multi-generational high-risk pedigrees. Thus far, no segregating risk 16 variants have been identified for MM. 17 
RESULTS

18
Pedigree analysis strategy 19 We developed a gene mapping strategy, based on the SGS method [16, 26] , that 20 accounts for intra-familial heterogeneity and multiple testing. The basic SGS method identifies 21 genomic segments shared identical-by-state (sharing without regard to inheritance) between a 22 defined set of cases using a dense genome-wide map of common single nucleotide 23 5 polymorphisms (SNPs), either from a genotyping platform or extracted from sequence data. If 1 the length of a shared segment is significantly longer than by chance, inherited sharing is 2 implied; theoretically, chance inherited sharing in distant relatives is extremely improbable. 3 Nominal chance occurrence (nominal p-value) for shared segments is assessed empirically 4 using gene-drop simulations to create a null distribution, as follows. Null genotype 5 configurations are generated by assigning haplotypes to pedigree founders according to a 6 publicly available linkage disequilibrium (LD) map, followed by segregation of these through the 7 pedigree structure to the case set via simulated Mendelian inheritance according to a genetic 8 (recombination) map. Gene-drops are performed independent of disease status and the 9 resulting genotype data in the case set are representative of chance sharing. This basic method 10 was shown to have excellent power in homogeneous pedigrees [16] . 11 In our new strategy, we iterate over all non-trivial combinations of the cases (subsets) in 12 each pedigree to address heterogeneity in a "brute-force" fashion. For each subset, shared 13 segments throughout the genome are identified and nominal p-values assigned. Across 14 subsets, an optimization procedure is performed at every marker across the genome to identify 15 the segment with the most significant sharing evidence. All shared segments selected by the 16 optimization procedure, and their respective p-values, comprise the final optimized SGS results. 17 To perform significance testing and identify segments that are unexpected by chance 18 (hypothesized to harbor risk loci), we derive significance thresholds to account for the genome-19 wide optimization. Acknowledging that the vast majority of observed sharing across a genome is 20 under the null (true risk loci are a very small minority of the genome), we use the observed 21 optimized results ( = − '( ( )) to model the distribution for optimized SGS results. We note 22 that this approach may be slightly conservative because signals for true risk loci are also 23 included. We identified the gamma distribution as adequate to represent the distribution (Fig. 1) . 24 Based on the fitted distribution, ~Γ( , ), where and and the shape and scale parameters, 25 6 we apply the Theory of Large Deviations; previously applied to successfully model genome-wide 1 fluctuations in linkage analysis [27] . The significance threshold, , accounts for multiple testing 2 of optimized segments across the genome, and is found by solving Eq. 1:
4 where = 10 =>? @ , = 2~@ B @ , ( ) is the genome-wide false positive rate required, ( ) 5 is nominal probability of exceeding , is the number of chromosomes considered, and is the 6 genome length in Morgans. A criterion of = 0.05 is typically used to define the genome-7 wide significant threshold (false positive rate of 0.05 per genome), and = 1 to define the 8 genome-wide suggestive threshold (false positive rate of 1 per genome).
9
In general, we found that the fitted distributions were sufficiently stable to produce robust 10 significance thresholds after 100,000-300,000 simulations ( producing larger numbers of segments). After optimization, = − '( for 6,697 to 10,369 8 segments were fit to gamma distributions for each pedigree, and used to determine genome-9 wide significant and suggestive thresholds (Eq. 1). The genome-wide significant thresholds 10 ranged from 6.2×10 -5 to 7.8×10 -7 and genome-wide suggestive from 8.2×10 -4 to 2.1×10 -5 (S1 11   Table) .
12
A genome-wide significant, 1.8 Mb shared segment (p = 3.3x10-6) was observed in 13 pedigree UT-571744. All three genotyped MM cases, separated by 20 meioses, share the 14 segment ( Fig. 2a and Table 2 ). The segment is located at chromosome 6q16 (98.49-100.24 Mb; 15 hg19) and includes 9 genes: POU3F2, FBXL4, FAXC, COQ3, PNISR, USP45, TSTD3, CCNC, 16 and PRDM13 (Figure 2b ). 17 We also identified two HRPs, UT-576834 and UT-260, with overlapping shared 1 segments at 1p36.11 ( Fig. 3) . A 8.9 Mb (24.39-33.30 Mb, p = 3.0×10-4) segment was observed 2 in 3 of the 4 genotyped MM cases in UT-576834, shared across 12 meioses ( Fig. 3b and Table   3 2). A nested 1.2 Mb shared segment (26.22-27.38 Mb; p = 2.1×10-4) segregated to 3 MM cases 4 separated by 16 meioses in UT-260 ( Fig. 3a and Table 2 ). The overlapping segment contains 5 30 genes ( Fig. 3d ). S3 Table) . We 10 reviewed SGS results in the Utah HRPs at the location of these 22 genes and identified a 11 genome-wide suggestive segment in pedigree UT-34955 (S2 Fig.) . This HRP identified a 0. ClinVar-annotated pathogenic variant, in a second early-onset MM case (S4 Table) . Further, 20 burden testing in all MM cases vs controls was significant in 7 of the 22 GG-NER genes: 21 ERCC3, PARP1, GTF2H1, GTF2H2, DDB1, RPA2, and CHD1L (S3 Table) .
22
ARID1A is a member of the SWI/SNF chromatin remodeling complex, a 15 gene 23 complex involved in DNA transcription regulation [37] (see S5 Table) . Members of this complex 24 11 are mutated in >20% of malignancies [38] [39] [40] , but are extremely intolerant to LoF and missense 1 variation [41] (S5 Table) . We reviewed SGS results in the Utah HRPs at the location of these 15 2 genes and identified a marginal, genome-wide suggestive segment in pedigree UT-549917 3 shared by 4 MM cases across 21 meioses (p = 2.17×10-5, S3 Fig. and S6 Table) . This 1. both large pedigrees and smaller families together for discovery (see Table 2 , Fig. 1 and Fig. 2) . 22 Post-hoc, additional value can be gained from demographic and/or clinical data on the sharing 23 12 subsets shedding light on other shared characteristics that may aid future mapping. Also, we 1 note that in the absence of any significant findings, genome-wide SGS results can be used as 2 genomic annotations of segregation evidence for more heuristic approaches. 3 While we identified several rare, potentially deleterious coding variants of interest, 4 several of the SGS discovery pedigrees had no coding variants that satisfied prioritization 5 criteria. We believe this will be characteristic of complex traits and that regulatory variants will 6 also play a substantial role. Mutations with strong causal likelihood found in other disease 7 cohorts may focus the search for regulatory variation to particular genes within a shared 8 segment, as with USP45 in MM. In the absence of such compelling evidence, a return to 9 pedigree segregation methods will provide identification of statistically compelling regions which 10 can concentrate efforts to identify and characterize regulatory risk variants. Our proposed 11 method is a new analytic tool with the potential to reinvigorate the use of extended HRPs in the 12 identification of risk variants that contribute to common, complex disease. 13 Multiple myeloma is a malignancy of the plasma cells that has been shown to be familial 14 [42] . Consistent with a role for genetics, case-control studies have been successful in identifying 15 association signals for 17 low-risk variants [43] [44] [45] [46] [47] . However, despite consistent evidence for 16 familial clustering, our study is the first to explore high-risk MM pedigrees. Using the unique 17 genealogical database available in Utah, we identified and studied extended MM HRPs. We 18 identified a genome-wide significant segment containing USP45, an important regulator of DNA 19 repair (see Fig. 1 and maintaining the DNA repair ability of ERCC1-ERCC4. In total, these observations implicate the 13 GG-NER pathway and specifically the interaction of USP45 and the disruption of the ERCC1-14 ERCC4 role in DNA repair as a mechanism of potential importance in MM risk. 15 Our strategy also identified shared segments overlapping at chr1p36.11 in two Utah 16 pedigrees containing ARID1A (Fig. 2) [16]). The method is not directly applicable to the many smaller family-based resources that 10 have been gathered in the complex trait field and may therefore result in findings from single 11 large pedigrees that are private and difficult to replicate. However, as illustrated in our example, 12 in a collaborative setting containing both extended HRPs and smaller families, the approach can 13 be mutually beneficial. Second, our observation of two borderline genome-wide suggestive 14 overlapping segments at 1p36 led to our identification of ARID1A as a potential candidate risk 15 gene and illustrates the potential for discoveries using overlapping subthreshold evidence. 16 However, it raises analytical questions of how to systematically identify such segments. This 17 segment would have been ignored based on strict individual-pedigree thresholds and highlights 18 an important area for further methodological development. Finally, this study is observational 19 and cannot describe causation. We have identified two complexes, several genes and specific 20 variants as compelling candidates involved in MM risk, but further functional studies will be 21 required to determine and characterize the mechanisms involved in risk.
In conclusion, we have developed a strategy for gene mapping in complex traits that 23 accounts for heterogeneity within HRPs and formally corrects for multiple testing to allow for 24 statistically rigorous discovery. We applied this strategy to MM, a complex cancer of plasma After SNP removal for low call rates, individuals were removed based on < 90% call rate across 20 the genome, or if they failed the PLINK sex check. One MM case was removed. The QC'ed 21 SNP data were transformed to match strand orientation of the 1000Genomes. Deviations has previously been used in pedigree studies to model extreme values in a genome 12 wide genetic setting [27] , and it has been shown that for a statistic following a Gaussian 13 distribution, the number of segments where the statistic exceeds a threshold has mean: Registry. We thank the participants and their families who make this research possible. 
